Healthcare Industry News: Roche
News Release - April 21, 2016
Symic Appoints Kathleen Gogas, Ph.D., as VP of Preclinical DevelopmentDr. Gogas brings over 20 years of industry experience to the company
SAN FRANCISCO, April 21, 2016 -- (Healthcare Sales & Marketing Network) -- Symic, a clinical-stage biotherapeutics company developing multiple compounds that target the extracellular matrix, today announced the appointment of Kathleen Gogas, Ph.D., as Vice President of Preclinical Development. Dr. Gogas will lead the company's research efforts in preclinical pharmacology and oversee IND enabling research.
"As our clinical programs for vascular injury and osteoarthritis advance, we can direct more attention to our diverse early stage pipeline and the selection of additional candidates for clinical development," said Ken Horne, Chief Executive Officer of Symic. "Dr. Gogas' experience with product candidates at the stage of preclinical research will add invaluable expertise to our management team as we seek to expand our pipeline by evaluating additional compounds that target and affect the extracellular matrix."
Dr. Gogas brings over 20 years of experience in advancing drug candidates from discovery through clinical trials and regulatory submission. Prior to joining Symic, Dr. Gogas was Senior Director of Preclinical Pharmacology at Nektar Therapeutics where she was responsible for all global preclinical research and development activities. These activities included projects in the areas of oncology, inflammation and pain. Dr. Gogas previously held leadership positions at Xenoport Inc., Neurocrine Biosciences and Roche Pharmaceuticals. Dr. Gogas received her Ph.D. in Pharmacology from Albany Medical College and conducted postdoctoral research at the University of California, San Francisco and Harvard University.
Symic is a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, which are important structural and functional macromolecules native to the ECM, play a critical role in healing following injury and in chronic diseases. Symic's proprietary compounds function like proteoglycans, and have been designed to promote healing and repair in a variety of disease states. Symic has two clinical candidates, one in vascular injury and the other in osteoarthritis. In addition, Symic has several preclinical programs in oncology, fibrosis and CNS disorders.
Symic is based in San Francisco. For additional information, please visit the company's website at http://www.symic.bio or follow us on Twitter at www.twitter.com/symicbio and LinkedIn at www.linkedin.com/company/symic-bio/.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.